Teijin Pharma Ltd

Tokyo, Japan

Teijin Pharma Ltd

Tokyo, Japan

Time filter

Source Type

Patent
Teijin Pharma Ltd | Date: 2016-11-01

For reducing a discomfort feeling brought by wearing a breathing mask, a wearing tool for the breathing mask which covers nostrils of a user and supplies gas for breathing to the nostrils comprises a pair of connecting members each of which has a longitudinal shape and has a first end portion which is connected to the breathing mask, and a pair of fixing members each of which is connected to a second end portion of the fixing member and is plugged in the tragus of the user. Hence a discomfort feeling due to restraining around the head of the user can be reduced.


Patent
Teijin Pharma Ltd | Date: 2017-03-22

Provided is a novel pyrazine derivative represented by the following formula (I) or a pharmaceutically acceptable salt thereof, or a solvate thereof which is useful for treating or preventing diseases in which URAT1 is involved, including gout, hyperuricemia, hypertension, renal diseases such as interstitial nephritis and the like, diabetes, arteriosclerosis, Lesch-Nyhan syndrome, and the like.


Disclosed are crystals of 2-(5-chloropyridin-3-yl)-1-(2,5-dichlorobenzyl)-4-methyl-1H-imidazole-5-carboxylic acid useful as therapeutic or prophylactic agents for gout, hyperuricemia, and the like, and a method for producing the crystals.


A rehabilitation assistance device (1), provided with: an arm part (30) having a holding part (20) for holding a part of the upper limb or the lower limb of a user, the arm part (30) movably supporting the holding part (20); a memory unit (80) for storing training information, the memory unit (80) storing first training information defined in advance; a motion information acquisition unit (61) for acquiring motion information associated with the movement of the holding part (20), the motion information acquisition unit (61) acquiring first motion information for the holding part (20) moved on the basis of the first training information; a motion evaluation unit (72) for generating evaluation information in which the motion information is evaluated, the motion evaluation unit (72) evaluating the first motion information and generating first evaluation information; and a display (40) for displaying at least one of the training information, the motion information, and the evaluation information.


Patent
Teijin Pharma Ltd and Amgen Inc. | Date: 2017-01-04

The present invention relates to a novel compound having a function of inhibiting ROR activity. The present invention also relates to pharmaceutical composition comprising the compound, a use of the compound in treating or preventing autoimmune diseases, inflammatory diseases, metabolic diseases, or cancer diseases.


Patent
Teijin Pharma Ltd | Date: 2017-06-07

There are provided crystals of 2-[4-(2,2-dimethylpropoxy)-3-(1H-1,2,3,4-tetrazol-1-yl)phenyl]-4-methyl-1,3-thiazole-5-carboxylic acid which is useful as a therapeutic agent or prophylactic agent for gout, hyperuricemia and the like.


Patent
Teijin Pharma Ltd | Date: 2017-06-07

There are provided: 4-methyl-2-[4-(2-methylpropoxy)-3-(1H-1,2,3,4-tetrazol-1-yl)phenyl]-1,3-thiazole-5-carboxylic acid, a sodium salt thereof and crystals of these, useful as a therapeutic agent and a prophylactic agent for gout, hyperuricemia and the like, and a method for producing the same.


Patent
Teijin Pharma Ltd | Date: 2017-05-31

Provided are a means to detect a plurality of dynamics, a processing unit that calculates a temporal change in the detected dynamics, and an evaluation device that determines exacerbation of clinical conditions in heart failure of a patient based on the calculated change in the patients dynamics over time. The present invention makes it possible to detect, early and with high accuracy, that the onset of acute heart failure is imminent.


Patent
Teijin Pharma Ltd | Date: 2017-08-02

Provided is an oxygen concentration device which, as an oxygen concentration device having a reduced difference in flow rates of gas which flows through a pressure equalization valve of a pressure equalization path during a purge step and a pressure equalization step, is provided at at least one end side of the pressure equalization valve with a pressure control member having a difference in pressure loss due to the direction of gas flow so that pressure loss of the gas which flows through the pressure equalization path in one direction becomes nearly equal to that of the gas which flows therethrough in the opposite direction.


Patent
Teijin Pharma Ltd | Date: 2016-06-03

The purpose of the present invention is to provide a novel therapeutic or prophylactic agent for tumor lysis syndrome. The present invention is a therapeutic or prophylactic agent for tumor lysis syndrome, which comprises a 2-phenylthiazole compound represented by formula (I) or a pharmaceutically acceptable salt thereof as an active ingredient.

Loading Teijin Pharma Ltd collaborators
Loading Teijin Pharma Ltd collaborators